ADVANCEMENT IN TREATMENT TECHNOLOGY FOR UTERINE LEIOMYOMA

Apply

ADVANCEMENT IN TREATMENT TECHNOLOGY FOR UTERINE LEIOMYOMA

Journal Title: Pharma Science Monitor-An International Journal Pharmaceutical Sciences - Year 2011, Vol 2, Issue 1

Abstract

Uterine leiomyomass, or fibroids, represent a major public health problem.This is most common female pelvic tumor, typically reported to occur in 20–40% of reproductive aged women, and up to 70% of white and 80% of black women by the age of 50 years Most fibroids are a symptomatic, but nearly half of women with fibroids have significant and often disabling symptoms including heavy menstrual bleeding, pain and pressure symptoms Traditionally, symptomatic fibroids have been treated with myomectomy or hysterectomy performed by laparotomy In an effort to reduce the cost, morbidity and lifestyle impact of major surgery, various less invasive or non-surgical procedures, new treatment approaches have become available to women with symptomatic fibroids. Undoubtedly the most significant therapeutic innovation has been the advent of uterine artery emobilization (UAE) as a form of non-surgical management. New technology has provided additional minimally invasive options such as percutaneous laser ablation, cryoablation, transvaginal uterine artery occlusion and magnetic resonance imaging (MRI)-guided focused ultrasound that are currently under intense investigation. Furthermore, new medications have been introduced, that show for practical, long-term medical therapy for symptomatic fibroids.

Authors and Affiliations

Ruby Rohilla , Jitender Madan , Gaurav Kumar

Keywords

Lieomyoma Hysterectomy myotomy uterine artery embolisation Laproscopic Gonadotrophin releasing hormones

EP ID EP113689
DOI -
Views 156
Downloads 0